

Abrogation of adenosine A₁ receptor signalling improves metabolic regulation in mice by modulating oxidative stress and inflammatory responses

Ting Yang¹ · Xiang Gao² · Monica Sandberg² · Christa Zollbrecht¹ · Xing-Mei Zhang³ · Michael Hezel¹ · Ming Liu¹ · Maria Peleli¹ · En-Yin Lai⁴ · Robert A. Harris³ · A. Erik G. Persson² · Bertil B. Fredholm¹ · Leif Jansson² · Mattias Carlström^{1,4}

Received: 22 January 2015 / Accepted: 2 March 2015 / Published online: 3 April 2015
© Springer-Verlag Berlin Heidelberg 2015

Abstract

Aims/hypothesis Adenosine is an important regulator of metabolism; however, the role of the A₁ receptor during ageing and obesity is unclear. The aim of this study was to investigate the effects of A₁ signalling in modulating metabolic function during ageing.

Methods Age-matched young and aged A₁ (also known as *Adora1*)-knockout (A₁^{-/-}) and wild-type (A₁^{+/+}) mice were used. Metabolic regulation was evaluated by body composition, and glucose and insulin tolerance tests. Isolated islets and islet arterioles were used to detect islet endocrine and vascular function. Oxidative stress and inflammation status were measured in metabolic organs and systemically.

Results Advanced age was associated with both reduced glucose clearance and insulin sensitivity, as well as increased

visceral adipose tissue (VAT) in A₁^{+/+} compared with A₁^{-/-} mice. Islet morphology and insulin content were similar between genotypes, but relative changes in in vitro insulin release following glucose stimulation were reduced in aged A₁^{+/+} compared with A₁^{-/-} mice. Islet arteriolar responses to angiotensin II were stronger in aged A₁^{+/+} mice, this being associated with increased NADPH oxidase activity. Ageing resulted in multiple changes in A₁^{+/+} compared with A₁^{-/-} mice, including enhanced NADPH oxidase-derived O₂⁻ formation and NADPH oxidase isoform 2 (Nox2) protein expression in pancreas and VAT; elevated levels of circulating insulin, leptin and proinflammatory cytokines (TNF-α, IL-1β, IL-6 and IL-12); and accumulation of CD4⁺ T cells in VAT. This was associated with impaired insulin signalling in VAT from aged A₁^{+/+} mice.

Conclusions/interpretation These studies emphasise that A₁ receptors regulate metabolism and islet endocrine and vascular functions during ageing, including via the modulation of oxidative stress and inflammatory responses, among other things.

Ting Yang and Xiang Gao are joint first authors.

Electronic supplementary material The online version of this article (doi:10.1007/s00125-015-3570-3) contains peer-reviewed but unedited supplementary material, which is available to authorised users.

✉ Mattias Carlström
mattias.carlstrom@ki.se

¹ Department of Physiology and Pharmacology, Karolinska Institutet, Nanna Svartz Väg 2, SE-171 77 Stockholm, Sweden

² Department of Medical Cell Biology, Uppsala University, Uppsala, Sweden

³ Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden

⁴ Division of Nephrology & Hypertension, and Hypertension, Kidney & Vascular Research Center, Georgetown University, Washington, DC, USA

Keywords Insulin sensitivity and resistance · Islets · Metabolic physiology in vivo · Metabolic syndrome · Oxidative stress · Type 2 diabetes · Visceral adipose tissue

Abbreviations

ANG II	Angiotensin II
DPCPX	8-Cyclopentyl-1,3-dipropylxanthine
DEXA	Dual-emission x-ray absorptiometry
GLP-1	Glucagon-like peptide-1
IPGTT	Intraperitoneal glucose tolerance test
IPITT	Intraperitoneal insulin tolerance test

Nox2	NADPH oxidase isoform 2
O ₂ ⁻	Superoxide anion
VAT	Visceral adipose tissue

Introduction

Type 2 diabetes is characterised by beta cell dysfunction and insulin resistance [1–3] leading to endothelial dysfunction with devastating long-term vascular impairment manifested as numerous complications [4, 5]. The incidence of type 2 diabetes increases with age and obesity, both of which are associated with oxidative stress and chronic inflammation. Mechanistic insights into the pathogenesis of type 2 diabetes and novel therapeutic approaches are urgently needed.

Several clinical and epidemiological studies have demonstrated that coffee consumption, mainly caffeine itself, is associated with a reduced risk of developing type 2 diabetes [6–8]. Caffeine inhibits the receptor-mediated actions of adenosine [9], which exerts biological effects via four types of receptors (A₁, A_{2A}, A_{2B} and A₃) [10]. Adenosine is an important regulator of metabolism; it modulates visceral adipose tissue (VAT) function through A₁ receptor-mediated actions in decreasing lipolysis and increasing lipogenesis [11, 12]. Studies utilising gene-modified mice have also suggested that the A₁ receptor interacts with insulin and glucagon signalling [13, 14] or secretion [15]. Adenosine was demonstrated to mediate metabolically induced vasodilation in several tissues [16, 17], and we have previously shown that A₁ receptor activation modulates *in vivo* islet blood flow in response to glucose [18].

These results, all obtained in younger animals, indicate that adenosine, via A₁ signalling, could affect glucose homeostasis in multiple ways. However, the role of the A₁ receptor in age-related metabolic disorders, which is an independent risk factor of type 2 diabetes [19–23], has not been clearly studied. We hypothesised that abrogation of A₁ receptor signalling attenuates metabolic dysfunction associated with ageing and obesity, by modulating islet function, oxidative stress and inflammatory responses. Indeed, our findings demonstrate this and may have therapeutic implications.

Methods

This study was approved by the Institutional Animal Care and Use Committee (IACUC) at Georgetown University, and by equivalent IACUCs in Uppsala and Stockholm, and was performed according to the National Institutes of Health guidelines for the conduct of experiments in animals.

Animals Experiments were conducted on adenosine A₁ receptor gene (also known as *Adora1*)-deleted (A₁^{-/-}) and wild-type mice (A₁^{+/+}) from heterozygous breeding pairs. The strain was developed by Johansson and co-workers [24] and backcrossed by the Jackson Laboratory (Bar Harbor, ME, USA) to a C57BL/6J background. Both sexes were used, with equal distribution for young (3–5 months) and aged (14–16 months) mice. Mice were housed in temperature-controlled rooms with 12 h light/dark cycles and received a standard rodent chow (4% fat, R36, Lactamin AB, Kimstad, Sweden) and tap water *ad libitum*.

Food intake and body composition analysis Food intake was assessed (96 h period) and dual-emission x-ray absorptiometry (DEXA) studies were performed using a Lunar PIXImus densitometer (GE Medical-Lunar, Madison, WI, USA) in isoflurane-anaesthetised (Forene; Abbott Scandinavia AB, Solna, Sweden) animals to determine fat and lean masses, as previously described [25].

Glucose and insulin tolerance test Intraperitoneal glucose (IPGTT) and insulin tolerance tests (IPITT) were performed, and the acute effects of pharmacological inhibition of the A₁ receptor with 8-cyclopentyl-1,3-dipropylxanthine (DPCPX), a potent and selective antagonist for the A₁ receptor (0.2 mg/kg body weight; Sigma-Aldrich; St Louis, MO, USA) or saline (154 mmol/l NaCl; placebo) were investigated. See Electronic Supplementary Material (ESM) [Methods](#) for further details.

Pancreatic islet arterioles: vascular reactivity studies Single islets with attached arterioles were dissected and perfused, as previously described [26]. Arteriolar responses to angiotensin II (ANG II; 10⁻⁶ to 10⁻¹² mol/l; Sigma-Aldrich) alone, or together with apocynin (10⁻⁴ mol/l; Sigma-Aldrich) were investigated during high (16.7 mmol/l) and low glucose (2.8 mmol/l). Dose-responses to adenosine (10⁻⁴ to 10⁻¹¹ mol/l; Sigma-Aldrich) were also investigated. See ESM [Methods](#) for further details.

Pancreatic islets: insulin release and contents Mouse pancreatic islets were isolated through collagenase digestion and cultured in groups of 150 islets for 3 days. Insulin release was measured in groups of ten islets from each animal after incubation with low (1.67 mmol/l) and high (16.7 mmol/l) glucose. Insulin content in the incubation media and homogenates were determined using a mouse insulin ELISA kit (Mercodia, Uppsala, Sweden) [27].

Lucigenin-dependent chemiluminescence of superoxide production NADPH oxidase-mediated superoxide (O₂⁻) formation was detected by lucigenin-dependent chemiluminescence assay [28]. Pancreas, liver and VAT were separately

homogenised and used for subsequent activity measurement. See ESM Methods for further details.

Plasma analysis Metabolic markers and cytokines were analysed in mouse blood samples using MesoScale Discovery Multi Array Technology (MSD, Rockville, MD, USA). See ESM Methods for further details.

Western blotting Pancreas, liver and VAT obtained from young and aged mice under basal conditions, after pretreatment with DPCPX (i.p. 0.2 mg/kg body weight) or 15 min after stimulation with insulin (i.p. 0.75 U/kg body weight), with and without DPCPX-pretreatment, were homogenised. Tissue extracts were prepared for SDS-PAGE followed by western blotting of NADPH oxidase isoform 2 (Nox2; BD Biosciences, Stockholm, Sweden), and total and phosphorylated Akt (Ser473; Cell Signaling/BioNordika, Stockholm, Sweden). Protein bands were quantified using densitometry and results are reported as relative optical density of the specific proteins.

Flow cytometric analysis Mouse tissues were incubated in digestion medium followed by erythrocyte lysis and cells were stained with antibodies specific for CD11b, F4/80, CD86, MHC II, CD3, CD4, CD8 α and respective isotype controls. Samples were analysed in a Gallios flow cytometer. See ESM Methods for further details.

Expression of adenosine receptors mRNA levels of adenosine A_1 , A_{2A} , A_{2B} and A_3 receptors in whole pancreas, VAT and isolated pancreatic islets together with islet arterioles were determined by quantitative PCR. See ESM Methods for further details.

Histology and insulin staining Pancreatic tissue was fixed and processed for evaluation of islet morphology, volume and insulin content. See ESM Methods for further details.

Data analysis Values are presented as means \pm SEM. Single comparisons between normally distributed variables were tested for significance using the Student's paired or unpaired *t* test, as appropriate. For multiple group comparisons, one-way ANOVA followed by Bonferroni's post hoc test was used to allow for more than one comparison with the same variable. Statistical significance was defined as $p < 0.05$.

Results

Animal characteristics Body weight was similar in young mice between genotypes. However, aged $A_1^{-/-}$ had slightly lower body weight than $A_1^{+/+}$ mice (Fig. 1a), despite similar daily food intake (Fig. 1b). DEXA analysis revealed an




Fig. 1 Body composition and food intake. Body weight (a) and food intake (b) were measured and DEXA was used to determine both total lean mass (c), lean mass fraction (d), total abdominal fat (e) and abdominal fat fraction (f) in young and in aged mice. Values are mean \pm SEM, $n = 20$ –32/group, except for (b) ($n = 16$ –20/group). * $p < 0.05$

ageing-related lean mass decrease (Fig. 1c, d) and abdominal fat increase (Fig. 1e, f) in $A_1^{+/+}$ but not in $A_1^{-/-}$ mice.

Glucose and insulin tolerance tests To investigate the role of A_1 receptors in modulating the metabolic phenotype during ageing, we performed glucose and insulin tolerance tests in young and aged mice. There was no difference in basal blood glucose levels or in glucose tolerance between genotypes in young mice (Fig. 2a). However, in aged mice, fasting blood glucose was somewhat higher in $A_1^{+/+}$ than in $A_1^{-/-}$ mice (6.7 ± 0.2 vs 5.9 ± 0.2 mmol/l, $p < 0.05$), and IPGTT revealed significantly better glucose homeostasis in aged $A_1^{-/-}$ mice (Fig. 2b, c). The glucose lowering effect of insulin was similar between genotypes at a young age (Fig. 2d). Ageing was associated with reduced insulin sensitivity (Fig. 2e) and increased AUC (Fig. 2f) in $A_1^{+/+}$, but not in $A_1^{-/-}$ mice.

To validate the effect of A_1 receptor inhibition on glucose tolerance and insulin sensitivity, paired crossover measurements were conducted in aged mice. DPCPX significantly improved both glucose (Fig. 2g) and insulin (Fig. 2j) responses in $A_1^{+/+}$ mice compared with placebo. These effects of the A_1 antagonist were not observed in $A_1^{-/-}$ mice (Fig. 2h, k). Corresponding AUCs are shown in Fig. 2i, l.




Fig. 2 IPGTT and IPITT. Plasma glucose levels were measured in IPGTT (a, b) and IPITT (d, e) in young (a, d; $n=14-18$) and aged (b, e; $n=28-32$) mice, respectively. The AUC ($\text{mmol l}^{-1} \text{min}^{-1}$) for the 0–120 min period was calculated for both glucose (c) and insulin (f) tolerance tests. To investigate the effects of A_1 receptor inhibition, paired crossover measurements were conducted in aged $A_1^{+/+}$ and $A_1^{-/-}$ mice given saline (placebo) or the A_1 receptor antagonist DPCPX 45 min prior to the IPGTT or the IPITT ($n=10-14/\text{group}$). Inhibition of A_1 receptor signalling significantly improved glucose clearance in $A_1^{+/+}$ (g), but had

no effect in $A_1^{-/-}$ mice (h). The AUC_{IPGTT} for the 0–120 min period was calculated (i). Inhibition of A_1 receptor signalling also improved the insulin response in $A_1^{+/+}$ (j), but had no effect in $A_1^{-/-}$ mice (k). The AUC_{IPITT} for the 0–120 min period was calculated (l). Black triangles, young $A_1^{+/+}$; white triangles, young $A_1^{-/-}$; black squares, aged $A_1^{+/+}$; white squares, aged $A_1^{-/-}$; dashed line, DPCPX treatment. Values are mean \pm SEM. * $p<0.05$ vs aged-matched $A_1^{-/-}$ mice, or among the indicated groups for AUC; † $p<0.05$ vs young mice of the same genotype; ‡ $p<0.05$ between placebo and DPCPX

Metabolic hormones in plasma Advanced age was associated with elevated levels of glucagon-like peptide-1 (GLP-1), glucagon, insulin and leptin in $A_1^{+/+}$ mice (Fig. 3a–d). However, ageing only induced a small leptin increase in $A_1^{-/-}$ mice. No significant differences were observed in these hormone concentrations between the genotypes at a young age.

Insulin release and insulin content in isolated islets To investigate specifically whether A_1 receptors modulate insulin release upon glucose challenge, we used isolated islets. High glucose concentrations stimulated insulin release in batch-type incubations in both young and aged $A_1^{+/+}$ and $A_1^{-/-}$ mice, but this response was attenuated during ageing (Fig. 4a). The relative insulin release response to glucose loading was significantly reduced in aged $A_1^{+/+}$ compared with young $A_1^{+/+}$ mice and also compared with age-matched $A_1^{-/-}$ mice (Fig. 4b). This effect could not be explained by differences

in total insulin content among the four groups investigated (Fig. 4c). In addition, the islet morphology was similar among groups (ESM Fig. 1). The number of islets was 0.58 ± 0.05 and 0.52 ± 0.07 per mg pancreas in young $A_1^{+/+}$ and $A_1^{-/-}$ mice, and 0.65 ± 0.11 and 0.70 ± 0.12 in aged $A_1^{+/+}$ and $A_1^{-/-}$ mice ($p>0.05$), respectively. Relative islet volume (%) was 1.16 ± 0.08 and 1.24 ± 0.09 in young $A_1^{+/+}$ and $A_1^{-/-}$ mice, and 1.18 ± 0.08 and 1.32 ± 0.13 in aged $A_1^{+/+}$ and $A_1^{-/-}$ mice ($p>0.05$), respectively. There were also no differences in pancreatic weight between young $A_1^{+/+}$ and $A_1^{-/-}$ mice (7.09 ± 0.20 vs 6.85 ± 0.46 mg/g body weight) or between aged $A_1^{+/+}$ and $A_1^{-/-}$ mice (8.05 ± 0.44 vs 8.02 ± 0.35 mg/g body weight).

Isolated and perfused islet arterioles To examine how the A_1 receptor influences the microvasculature, isolated and perfused pancreatic islet arterioles (Fig. 5a) were used for vascular reactivity studies. In aged mice, glucose-induced dilation




Fig. 3 Metabolic hormones in plasma. Plasma levels of GLP-1, glucagon, insulin and leptin (a–d) were determined using the MesoScale Discovery assay in young and aged mice. Values are mean \pm SEM, $n=12$ –16/group. * $p<0.05$

on afferent arterioles was similar between genotypes, but the subsequent contractile responses to ANG II were significantly attenuated in arterioles from $A_1^{-/-}$ mice (Fig. 5c). However, in young mice these differences were much less pronounced (Fig. 5b). Simultaneous incubation with apocynin, to inhibit NADPH oxidase activity, attenuated ANG II-mediated contractions in $A_1^{+/+}$ mice ($25\pm 1\%$ vs $12\pm 3\%$), but had no effect on arterioles from $A_1^{-/-}$ mice ($13\pm 3\%$ vs $12\pm 1\%$). With apocynin, the arteriolar responses were similar between




Fig. 4 Glucose-stimulated insulin release and insulin contents in islets. (a) Insulin release after low glucose (LG; 2.8 mmol/l) and high glucose (HG; 16.7 mmol/l) stimulation in islets. Insulin responses were calculated as percentage change (b), and the total insulin content was analysed (c). Values are mean \pm SEM, $n=8$ /group. * $p<0.05$

$A_1^{+/+}$ and $A_1^{-/-}$ mice (Fig. 5d), suggesting that the difference between genotypes could be related to the regulation of NADPH oxidase function and oxidative stress. There was no difference with regard to the arteriolar diameters among groups (ESM Fig. 2).

NADPH oxidase-mediated superoxide production and Nox2 level To investigate further whether oxidative stress contributes to the pathogenesis of age-related metabolic disorders, O_2^- formation was measured in pancreas, liver and VAT. Ageing was associated with increased O_2^- generation in pancreas (Fig. 6a) and VAT (Fig. 6b) from $A_1^{+/+}$ mice. In $A_1^{-/-}$ mice, this age-dependent change was much less and only occurred in pancreas. In agreement with this, the protein levels of Nox2 in both pancreas (Fig. 6c, e) and VAT (Fig. 6d, f) were significantly increased in $A_1^{+/+}$ mice during ageing while no significant changes were observed in $A_1^{-/-}$ mice. Moreover, the Nox2 level in VAT in aged $A_1^{+/+}$ was significantly higher compared with that in $A_1^{-/-}$ mice. No differences between genotypes were revealed in young mice. NADPH oxidase activity and Nox2 levels in liver were similar between genotypes and did not change with ageing.

Cytokines in plasma Considering the interaction between oxidative stress and inflammation, we measured systemic cytokine levels to investigate if abrogation of A_1 receptor signalling also influenced the inflammatory status. Advanced age was associated with elevated circulating TNF- α , IL-1 β , IL-6, IL-12 and IL-10 levels in $A_1^{+/+}$ mice, but in aged $A_1^{-/-}$ mice only IL-10 was elevated (Fig. 7a–e). In agreement with this, the proinflammatory cytokines levels were significantly higher in aged $A_1^{+/+}$ mice compared with age-matched $A_1^{-/-}$ mice. No differences of the cytokines investigated were observed between genotypes in young mice.

Populations of macrophages and T cells in VAT To further understand the potential role of A_1 signalling in regulating inflammation during ageing and metabolic disorder, flow cytometric analysis was performed on single-cell suspensions extracted from VAT (Fig. 8a). There were no significant differences in total macrophage population in either young or aged mice between genotypes (Fig. 8b, d), but the number of CD86⁺ macrophages was significantly higher in aged $A_1^{-/-}$ mice compared with age-matched $A_1^{+/+}$ mice (Fig. 8c). $A_1^{+/+}$ mice showed an age-related enhancement of total T cells and specifically of the CD4⁺ T cell population, this not being evident in $A_1^{-/-}$ mice (Fig. 8e, f). There were no differences regarding numbers of macrophages and T cells in the pancreas or liver.

Akt phosphorylation in VAT To examine if the difference in insulin sensitivity, oxidative stress and immune cell population was manifested in a downstream cellular event, we




Fig. 5 Islet arteriolar reactivity. The micrograph shows the experimental set-up (a) with an isolated and perfused islet arteriole (scale bar, 50 μ m). (b–d) Changes in luminal diameter of the arteriole were measured in response to high glucose (HG; 16.7 mmol/l) and cumulative doses of ANG II from 1 pmol/l (1×10^{-12}) to 1 μ mol/l (1×10^{-6}) in young mice (b), aged mice (c) and with simultaneous inhibition of NADPH oxidase

with apocynin (10^{-4} mol/l) (d). Black triangles, young $A_1^{+/+}$; white triangles, young $A_1^{-/-}$; black squares, aged $A_1^{+/+}$; white squares, aged $A_1^{-/-}$; dashed line, apocynin treatment. Values are mean \pm SEM, $n=8$ /group. * $p<0.05$ compared with age-matched $A_1^{-/-}$ mice; † $p<0.05$ compared with arterioles from aged-matched $A_1^{+/+}$ mice without simultaneous apocynin treatment (c)




Fig. 6 Superoxide production and Nox2 level in pancreas and VAT. NADPH oxidase-derived superoxide formation in whole pancreas (a) and VAT (b) were measured with lucigenin-dependent chemiluminescence signal (CLU, chemiluminescence unit). Western blot was used to detect Nox2 level in pancreas (c, e) and VAT (d, f). Part (c, d) illustrates two representative samples per group obtained from different gels. Expression levels were normalised to β -actin after densitometric quantification. Values are mean \pm SEM, $n=10$ –16/group. * $p<0.05$; † $p=0.08$

determined Akt and Akt phosphorylation in VAT from young and aged $A_1^{+/+}$ and $A_1^{-/-}$ mice, and in aged mice 15 min following i.p. injection with insulin (0.75 U/kg body weight) (Fig. 9a–d). There were no differences in basal Akt and p-Akt levels between genotypes (Fig. 9b, c), but ageing was associated with significantly higher p-Akt/Akt ratio in aged $A_1^{+/+}$ compared with young $A_1^{+/+}$ mice (Fig. 9d). Importantly, insulin-induced phosphorylation of Akt was markedly increased in $A_1^{-/-}$, but not significantly changed in age-matched $A_1^{+/+}$ mice (Fig. 9d). In another cohort, mice were treated with DPCPX 45 min prior to the insulin challenge. DPCPX alone did not change the expression and phosphorylation levels of Akt. However, acute inhibition of A_1 receptor signalling increased p-Akt and p-Akt/Akt ratio following insulin challenge in the $A_1^{+/+}$ mice, to the same level as in the $A_1^{-/-}$ (Fig. 9e–h).

Expression of adenosine receptors To clarify if the different metabolic phenotypes during ageing and between $A_1^{+/+}$ and $A_1^{-/-}$ mice were attributable to the possible differences of adenosine receptors expression, we used quantitative PCR to determine the expression of all four subtypes of adenosine receptors in pancreas (ESM Fig. 3a–d), islets together with their arterioles (ESM Fig. 3e–h) and in VAT (ESM Fig. 3i–l). The A_1 receptor gene expression was undetectable in $A_1^{-/-}$ mice. In all tissues, no differences in A_{2A} , A_{2B} and A_3 receptor expression between genotypes were observed in either young or aged mice. The same adenosine receptor subtypes were also similarly expressed in young and aged mice of the same genotype.




Fig. 7 Cytokines in plasma. Plasma levels of TNF- α , IL-1 β , IL-6, IL-12 and IL-10 (a–e) were determined using the MesoScale Discovery assay in young and aged mice. There were no differences of plasma IFN- γ and keratinocyte-derived chemokine/growth-related oncogene (KC/GRO) among groups (data not shown). Values are mean \pm SEM, $n=12$ –16/group. * $p<0.05$

Discussion

Our major finding is that abrogation of A_1 signalling improves the metabolic profile during ageing. The underlying mechanisms are multifactorial: besides the known direct actions on lipolysis and lipogenesis [11, 12], we found actions on peripheral insulin signalling, presumably via attenuation of NADPH oxidase function, as well as modulation of inflammatory pathways in VAT apparently being involved. Moreover, direct effects of A_1 signalling on the islet microvasculature, and insulin release, are also involved.

We observed an age-dependent reduction in lean mass and an accumulation of VAT in wild-type but not in $A_1^{-/-}$ mice. This is entirely compatible with previous studies showing that endogenous adenosine, through A_1 receptor signalling, reduces lipolysis and enhances lipogenesis [29]. We also found that advanced age was associated with elevated blood glucose levels, impaired glucose tolerance and insulin responses or signalling in $A_1^{+/+}$ but not in $A_1^{-/-}$ mice. Pharmacological inhibition of the A_1 receptor improved glucose tolerance in aged wild-type mice, but had no effect in A_1 knockouts. Our


data indicate that not only acute intervention of A_1 receptors will affect the metabolic function, but that A_1 receptors are also participating in the metabolic derangement in mice during ageing. Taken together, these findings demonstrate that A_1 receptor signalling influences both VAT and glucose regulation during ageing and emphasise the potential therapeutic value of targeting of A_1 receptors in type 2 diabetes.

Adenosine is known to affect the endocrine pancreas per se [30], and previous studies suggested that adenosine receptors can modulate insulin and glucagon secretion [13]. We found advanced age to be associated with an elevation of insulin, glucagon, GLP-1 and leptin in $A_1^{+/+}$ mice, but in aged $A_1^{-/-}$ mice only leptin levels were increased. Thus, the beneficial effect of eliminating A_1 receptor signalling was extended to the hormone status. Increased leptin concentration or resistance were suggested as contributing to the inflammatory status in adipose tissue [31] and have been linked to age-associated disorders including obesity, cardiovascular diseases, the metabolic syndrome and diabetes [32–36]. Elevated glucagon levels and insulin resistance are generally thought to contribute to the pathophysiology of hyperglycaemia in individuals with type 2 diabetes.

Our islet studies demonstrated that the absence of A_1 receptors does not directly affect islet morphology or insulin content. However, ageing was associated with reduced glucose-stimulated insulin release in wild-type mice, but this age-dependent reduction was not observed in $A_1^{-/-}$ mice. Islet blood flow is normally coupled to islet insulin release [37, 38]. To provide a better possibility to study only the islet afferent arteriole, we used a recently developed technique with isolated and perfused single islets with attached arterioles [26]. Similar to that recently described for renal afferent arterioles [39], islet arterioles from $A_1^{-/-}$ mice displayed reduced contractility to ANG II. This was apparent during both normo- and hyperglycaemic conditions, although much more profound during the latter. Since the baseline diameters of the islet arterioles were similar in all the groups, one may speculate that, at physiological ANG II concentrations, aged $A_1^{+/+}$ mice would have an increased arteriolar resistance. However, future studies with other techniques are required to confirm this hypothesis.

Oxidative stress, particularly O_2^- , has been demonstrated to reduce islet blood flow [40]. ANG II stimulates NADPH oxidase-mediated O_2^- formation, which contributes to its pronounced vasoactive properties. Interestingly, reduction of oxidative stress by the NADPH oxidase inhibitor apocynin attenuated ANG II-mediated contraction in $A_1^{+/+}$ mice, but had no effect on islet arterioles from $A_1^{-/-}$ mice. This suggests an important role of the adenosine A_1 receptor in modulating O_2^- production. This notion has also been described in models of ANG II-induced hypertension in which blood pressure elevation and oxidative stress were markedly attenuated in A_1 gene-deleted mice [39, 41].

Fig. 8 Macrophages and T cell populations in VAT. Part (a) depicts the gating strategy. No significant differences in total macrophages ($CD11b^+F4/80^+$) and $MHCII^+$ macrophages ($CD11b^+MHCII^+$) were evident between genotypes (b, d). However, $CD86^+$ macrophages ($CD11b^+CD86^+$) were significantly higher in aged $A_1^{-/-}$ mice compared with age-matched $A_1^{+/+}$ mice (c). T cell population analysis revealed an age-dependent increase of total T cells ($CD3^+CD11b^+$) and $CD4^+$ T cells ($CD3^+CD4^+$) in $A_1^{+/+}$ mice, but this phenotype was absent in $A_1^{-/-}$ mice (e, f). No differences were evident in $CD8^+$ T cell populations ($CD3^+CD8^+$) between genotypes at different ages (g). Values are mean \pm SEM, $n=6$ /group. * $p<0.05$; † $p=0.1$




Increasing evidence from experimental and clinical studies has demonstrated that oxidative stress and inflammation are key factors that contribute to the progression of metabolic disorders including type 2 diabetes [42, 43]. In the present study we show that ageing is associated with increased NADPH oxidase-derived O_2^- formation, together with higher Nox2 levels, in both pancreas and VAT from $A_1^{+/+}$ mice. This age-dependent elevation in O_2^- formation and oxidative stress was clearly attenuated, or even absent, in gene-deleted animals, which certainly may contribute to their better metabolic phenotype.

Age-related VAT accumulation is associated with a chronic, low-grade inflammation and has been increasingly recognised as an independent risk factor of the pathogenesis of type 2 diabetes [44–46]. Almost all immune cell subsets are present in VAT. Their functions are still under discussion, although it is generally accepted that total T cell and macrophage

populations are increased and contribute to the meta-inflammation evident in obesity. We did not discern differences in total macrophages among groups, but observed a significant enhancement of the $CD86^+$ macrophage population in aged $A_1^{-/-}$ mice, indicating elevated antigen presentation capacity. Interestingly, another recent study reported a lipolysis-related macrophage infiltration in adipose tissue without presenting pro-inflammatory characters [47]. As $A_1^{-/-}$ mice have elevated lipolysis and remain lean, this enhancement of $CD86^+$ macrophages may be due to a response to the continuous release of non-esterified fatty acids. As young mice have much lower lipolysis levels, no differences (e.g. in fat mass) were evident between genotypes at an early age. However, ageing resulted in a significant increase of total T cells and $CD4^+$ T cells in VAT in $A_1^{+/+}$ mice, while this was not the case in $A_1^{-/-}$ mice. In addition, levels of circulating proinflammatory cytokines (including TNF- α , IL-1 β , IL-6

Fig. 9 Phosphorylation of Akt in VAT. Parts (a, e) illustrate three representative samples per group obtained from different gels.


Expression levels were normalised to β -actin, and results after densitometric quantification are shown for p-Akt (b), total Akt (c) and relative p-Akt-to-Akt levels (d). Acute A_1 inhibition with DPCPX, followed by insulin challenge, increased p-Akt and p-Akt/Akt ratio in the $A_1^{+/+}$ mice to the same level as in the $A_1^{-/-}$ mice (e–h). Values are mean \pm SEM, $n=6$ /group. * $p<0.05$



and IL-12) were increased in aged $A_1^{+/+}$ but not in $A_1^{-/-}$ mice. These findings indicate that a sustained inflammation occurs during ageing and obesity, and may lead to subsequent metabolic disorders, as has been previously suggested [48, 49]. Moreover, accumulation of $CD4^+$ T cells in VAT may be a key contributor to this systemic inflammation and can be modulated via A_1 receptor signalling. Further investigations on the immunomodulation effects of the A_1 receptor during ageing

and the metabolic syndrome are needed and will provide additional insights in developing therapeutic strategies for type 2 diabetes. It seems likely that decreased VAT accumulation and inflammation may contribute to the better metabolic regulation in the $A_1^{-/-}$ mice during ageing, including better insulin sensitivity. Indeed, our data show significantly better insulin signalling in aged $A_1^{-/-}$ mice, as demonstrated by increased phosphorylation of Akt kinase in VAT upon insulin

Fig. 10 Proposed effects of the adenosine A_1 receptor in modulating metabolic derangement during ageing



stimulation. This insulin signalling pathway was markedly reduced in aged-matched wild-type mice and may contribute to their impaired glucose clearance function.

Besides the A_1 receptor, also adenosine receptor A_{2A} and A_{2B} play a role in modulating glucose homeostasis and obesity [50, 51]. We did not reveal any significant differences regarding the A_2 and A_3 receptor expression among the groups, suggesting no compensatory changes following A_1 receptor deletion. Thus, we believe the improved metabolic phenotypes in the $A_1^{-/-}$ mice in our study were due to the abrogation of A_1 signalling and our findings further suggest a pivotal role of the A_1 receptor in modulating especially the function of VAT, which may affect the metabolic homeostasis.

In conclusion, the present study demonstrates an important role of the adenosine A_1 receptor in modulating glucose and insulin homeostasis, as well as islet endocrine and arteriolar function, during ageing. Mechanistically, our findings suggest that abrogation of A_1 signalling may protect from age-dependent oxidative stress and production of pro-inflammatory cytokines, and hence improve insulin release and signalling (Fig. 10). Thus, abrogation of A_1 receptor signalling can both have acute effects and give long-term prevention of the development or progression of diabetes. Future studies in humans should be aimed at determining the therapeutic value of modulating A_1 signalling.

Acknowledgements We thank E. Lindgren (Karolinska Institutet) and M. Quach (Uppsala University) for technical assistance and helpful discussions.

Funding This work was supported by grants from the Swedish Research Council (521-2011-2639 to MC and 521-2011-3777 to LJ), Swedish Heart and Lung Foundation (20140448, 20110589), Jeansson's Foundation (JS2013-00064), Swedish Diabetes Foundation, an EXODIAb grant, Swedish Society of Medical Research (SSMF), the Wenner-Gren Foundation, the Family Ernfors Fund, the Swedish Society of Medicine and Novo Nordisk Foundation Excellence Project.

Duality of interest The authors declare that there is no duality of interest associated with this manuscript.

Contribution statement MC, LJ, BBF and TY designed the study and wrote the manuscript. All authors made substantial contributions to conception and design, acquisition of data, or analysis and interpretation of data, and revised the article critically for important intellectual content. All authors approved the final version of the manuscript to be published. MC is the guarantor of this work and, as such, had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

References

- Defronzo RA (2009) Banting Lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus. *Diabetes* 58:773–795
- Nolan CJ, Damm P, Prentki M (2011) Type 2 diabetes across generations: from pathophysiology to prevention and management. *Lancet* 378:169–181
- Weir GC, Laybutt DR, Kaneto H, Bonner-Weir S, Sharma A (2001) Beta-cell adaptation and decompensation during the progression of diabetes. *Diabetes* 50(Suppl 1):S154–S159
- Antonetti DA, Klein R, Gardner TW (2012) Diabetic retinopathy. *N Engl J Med* 366:1227–1239
- Ferrannini E, Cushman WC (2012) Diabetes and hypertension: the bad companions. *Lancet* 380:601–610
- Beaudoin MS, Graham TE (2011) Methylxanthines and human health: epidemiological and experimental evidence. *Handb Exp Pharmacol* 200:509–548
- Loopstra-Masters RC, Liese AD, Haffner SM, Wagenknecht LE, Hanley AJ (2011) Associations between the intake of caffeinated and decaffeinated coffee and measures of insulin sensitivity and beta cell function. *Diabetologia* 54:320–328
- Bhupathiraju SN, Pan A, Manson JE, Willett WC, van Dam RM, Hu FB (2014) Changes in coffee intake and subsequent risk of type 2 diabetes: three large cohorts of US men and women. *Diabetologia* 57:1346–1354
- Fredholm BB, Battig K, Holmen J, Nehlig A, Zvartau EE (1999) Actions of caffeine in the brain with special reference to factors that contribute to its widespread use. *Pharmacol Rev* 51:83–133
- Fredholm BB, IJzerman AP, Jacobson KA, Linden J, Muller CE (2011) International Union of Basic and Clinical Pharmacology. LXXXI. Nomenclature and classification of adenosine receptors—an update. *Pharmacol Rev* 63:1–34
- Dhalla AK, Chisholm JW, Reaven GM, Belardinelli L (2009) A_1 adenosine receptor: role in diabetes and obesity. *Handb Exp Pharmacol*: 271–295
- Fredholm BB, Johansson S, Wang YQ (2011) Adenosine and the regulation of metabolism and body temperature. *Adv Pharmacol* 61:77–94
- Johansson SM, Salehi A, Sandstrom ME et al (2007) A_1 receptor deficiency causes increased insulin and glucagon secretion in mice. *Biochem Pharmacol* 74:1628–1635
- Salehi A, Parandeh F, Fredholm BB, Grapengiesser E, Hellman B (2009) Absence of adenosine A_1 receptors unmasks pulses of insulin release and prolongs those of glucagon and somatostatin. *Life Sci* 85:470–476
- Yang GK, Fredholm BB, Kieffer TJ, Kwok YN (2012) Improved blood glucose disposal and altered insulin secretion patterns in adenosine A_1 receptor knockout mice. *Am J Physiol Endocrinol Metab* 303:E180–190
- Deshpande NA, McDonald TJ, Cook MA (1999) Endogenous interstitial adenosine in isolated myenteric neural networks varies inversely with prevailing PO_2 . *Am J Physiol* 276:G875–885
- Collis MG (1989) The vasodilator role of adenosine. *Pharmacol Ther* 41:143–162
- Carlsson PO, Olsson R, Kallskog O, Bodin B, Andersson A, Jansson L (2002) Glucose-induced islet blood flow increase in rats: interaction between nervous and metabolic mediators. *Am J Physiol Endocrinol Metab* 283:E457–464
- Chang AM, Halter JB (2003) Aging and insulin secretion. *Am J Physiol Endocrinol Metab* 284:E7–12
- Gabriely I, Ma XH, Yang XM et al (2002) Removal of visceral fat prevents insulin resistance and glucose intolerance of aging: an adipokine-mediated process? *Diabetes* 51:2951–2958
- Hanley AJ, Wagenknecht LE, Norris JM et al (2009) Insulin resistance, beta cell dysfunction and visceral adiposity as predictors of incident diabetes: the Insulin Resistance Atherosclerosis Study (IRAS) Family study. *Diabetologia* 52:2079–2086
- Kahn SE, Hull RL, Utzschneider KM (2006) Mechanisms linking obesity to insulin resistance and type 2 diabetes. *Nature* 444:840–846

23. Ling C, Groop L (2009) Epigenetics: a molecular link between environmental factors and type 2 diabetes. *Diabetes* 58:2718–2725
24. Johansson B, Halldner L, Dunwiddie TV et al (2001) Hyperalgesia, anxiety, and decreased hypoxic neuroprotection in mice lacking the adenosine A1 receptor. *Proc Natl Acad Sci U S A* 98:9407–9412
25. Nagy TR, Clair AL (2000) Precision and accuracy of dual-energy X-ray absorptiometry for determining in vivo body composition of mice. *Obes Res* 8:392–398
26. Lai EY, Jansson L, Patzak A, Persson AE (2007) Vascular reactivity in arterioles from normal and alloxan-diabetic mice: studies on single perfused islets. *Diabetes* 56:107–112
27. Datla SR, Griendling KK (2010) Reactive oxygen species, NADPH oxidases, and hypertension. *Hypertension* 56:325–330
28. Carlstrom M, Brown RD, Yang T et al (2013) L-arginine or tempol supplementation improves renal and cardiovascular function in rats with reduced renal mass and chronic high salt intake. *Acta Physiol (Oxf)* 207:732–741
29. Johansson SM, Lindgren E, Yang JN, Herling AW, Fredholm BB (2008) Adenosine A1 receptors regulate lipolysis and lipogenesis in mouse adipose tissue—interactions with insulin. *Eur J Pharmacol* 597:92–101
30. Burnstock G, Novak I (2012) Purinergic signalling in the pancreas in health and disease. *J Endocrinol* 213:123–141
31. Kaminski DA, Randall TD (2010) Adaptive immunity and adipose tissue biology. *Trends in immunology* 31:384–390
32. Friedman JM, Halaas JL (1998) Leptin and the regulation of body weight in mammals. *Nature* 395:763–770
33. Galletti F, Barbato A, Versiero M et al (2007) Circulating leptin levels predict the development of metabolic syndrome in middle-aged men: an 8-year follow-up study. *J Hypertens* 25:1671–1677
34. Moran O, Phillip M (2003) Leptin: obesity, diabetes and other peripheral effects—a review. *Pediatr Diabetes* 4:101–109
35. Patel SB, Reams GP, Spear RM, Freeman RH, Villarreal D (2008) Leptin: linking obesity, the metabolic syndrome, and cardiovascular disease. *Curr Hypertens Rep* 10:131–137
36. Sader S, Nian M, Liu P (2003) Leptin: a novel link between obesity, diabetes, cardiovascular risk, and ventricular hypertrophy. *Circulation* 108:644–646
37. Jansson L (1994) The regulation of pancreatic islet blood flow. *Diabetes Metab Rev* 10:407–416
38. Brunicaardi FC, Stagner J, Bonner-Weir S et al (1996) Microcirculation of the islets of Langerhans. Long beach veterans administration regional medical education center symposium. *Diabetes* 45:385–392
39. Gao X, Patzak A, Sendeski M et al (2011) Adenosine A(1)-receptor deficiency diminishes afferent arteriolar and blood pressure responses during nitric oxide inhibition and angiotensin II treatment. *Am J Physiol Regul Integr Comp Physiol* 301:R1669–1681
40. Svensson AM, Sandler S, Jansson L (2003) Role of superoxide anion in pancreatic islet blood flow regulation in anesthetized rats. *Eur J Pharmacol* 459:59–64
41. Lee DL, Bell TD, Bhupatkar J, Solis G, Welch WJ (2012) Adenosine A1-receptor knockout mice have a decreased blood pressure response to low-dose ANG II infusion. *Am J Physiol Regul Integr Comp Physiol* 303:R683–688
42. Youn JY, Siu KL, Lob H, Itani H, Harrison DG, Cai H (2014) Role of vascular oxidative stress in obesity and metabolic syndrome. *Diabetes* 63:2344–2355
43. Wellen KE, Hotamisligil GS (2005) Inflammation, stress, and diabetes. *J Clin Invest* 115:1111–1119
44. Shu CJ, Benoist C, Mathis D (2012) The immune system's involvement in obesity-driven type 2 diabetes. *Semin Immunol* 24:436–442
45. Odegaard JI, Chawla A (2013) The immune system as a sensor of the metabolic state. *Immunity* 38:644–654
46. Cildir G, Akinçilar SC, Tergaonkar V (2013) Chronic adipose tissue inflammation: all immune cells on the stage. *Trends Mol Med* 19:487–500
47. Kosteli A, Sugaru E, Haemmerle G et al (2010) Weight loss and lipolysis promote a dynamic immune response in murine adipose tissue. *J Clin Invest* 120:3466–3479
48. Kern PA, Ranganathan S, Li C, Wood L, Ranganathan G (2001) Adipose tissue tumor necrosis factor and interleukin-6 expression in human obesity and insulin resistance. *Am J Physiol Endocrinol Metab* 280:E745–751
49. Hotamisligil GS, Arner P, Caro JF, Atkinson RL, Spiegelman BM (1995) Increased adipose tissue expression of tumor necrosis factor- α in human obesity and insulin resistance. *J Clin Invest* 95:2409–2415
50. Johnston-Cox H, Koupenova M, Yang D et al (2012) The A2b adenosine receptor modulates glucose homeostasis and obesity. *PLoS One* 7:e40584
51. Gnad T, Scheibler S, von Kugelgen I et al (2014) Adenosine activates brown adipose tissue and recruits beige adipocytes via A2A receptors. *Nature* 516:395–399